The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
 
Mairead Geraldine McNamara
Honoraria - Advanced Accelerator Applications (Inst); Novartis
Consulting or Advisory Role - AstraZeneca (Inst); Incyte; Ipsen; Shire; Sirtex Medical
Speakers' Bureau - Nucana
Research Funding - Ipsen; Nucana; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Novartis
 
Jayne Swain
No Relationships to Disclose
 
Zoe Craig
Research Funding - Amgen (Inst); Celgene (Inst); Merck (Inst); Takeda (Inst)
 
Rohini Sharma
No Relationships to Disclose
 
Olusola Olusesan Faluyi
No Relationships to Disclose
 
Jonathan Wadsley
Consulting or Advisory Role - Bayer (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
Speakers' Bureau - Eisai; Genzyme
Research Funding - AstraZeneca; Genzyme
 
Carys Morgan
Honoraria - Bristol Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Lucy R. Wall
Research Funding - Merck Serono
 
Ian Chau
Honoraria - Eisai; Lilly; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Nick Reed
Honoraria - Ipsen; Lilly; Novartis; Roche
Consulting or Advisory Role - Eisai; Ipsen; Merck; Novartis; Seagen
Research Funding - Exelixis (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst)
 
Debashis Sarker
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - AAA HealthCare; Bayer; Eisai; Ipsen; Novartis; Roche; Sirtex Medical; Surface Oncology; UCB (Inst)
Speakers' Bureau - AstraZeneca; Bayer; Eisai
Research Funding - UCB (Inst)
Travel, Accommodations, Expenses - MiNA Therapeutics
(OPTIONAL) Uncompensated Relationships - Medivir; MINA THERAPEUTICS
 
Jane Margetts
No Relationships to Disclose
 
Daniel Krell
No Relationships to Disclose
 
Judith Cave
No Relationships to Disclose
 
Sothi Sharmila
No Relationships to Disclose
 
Alan Anthoney
No Relationships to Disclose
 
Alkesh Patel
No Relationships to Disclose
 
Angela Lamarca
Consulting or Advisory Role - Albireo Pharma; AstraZeneca/MedImmune; Boston Scientific; Eisai; Ipsen; Nutricia; Nutricia (I); QED Therapeutics; Roche; SERVIER
Speakers' Bureau - Advanced Accelerator Applications; AstraZeneca/MedImmune; Eisai; Incyte; Ipsen; Ipsen (I); Merck; Novartis (I); Pfizer; Pfizer (I); QED Therapeutics; SERVIER
Research Funding - Ipsen; Ipsen (I); Roche
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Bayer; Celgene; Delcath Systems; Ipsen; Ipsen (I); Mylan; NanoString Technologies (I); Novartis; Pfizer; Sirtex Medical
 
Richard Hubner
No Relationships to Disclose
 
Juan W. Valle
Consulting or Advisory Role - Aptitude Health; AstraZeneca; Autem Medical; Baxter; Boehringer Ingelheim; Cantargia AB; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Taiho Oncology; Wren Laboratories; Zymeworks
Speakers' Bureau - Delcath Systems; Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Lilly; Nucana; Roche